Marker Therapeutics (MRKR) Non-Current Assets (2010 - 2023)

Marker Therapeutics (MRKR) has 10 years of Non-Current Assets data on file, last reported at $17.0 million in Q1 2023.

• Non-Current Assets for Q1 2023 came in at $17.0 million, down 28.87% year-over-year; the trailing twelve-month figure through Mar 2023 was $17.0 million (down 28.87% YoY), and the FY2022 annual result was $17.8 million, down 19.64% from the prior year.
• Non-Current Assets declined to $17.0 million in Q1 2023 per MRKR's latest filing, from $17.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $23.9 million in Q1 2022 and troughed at $872702.0 in Q4 2019.
• A 5-year average of $14.3 million and a median of $18.2 million in 2020 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2020 and 2023: Non-Current Assets surged 2329.69% in 2020, then decreased 28.87% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $872702.0 in 2019, then surged by 2329.69% to $21.2 million in 2020, then rose by 4.48% to $22.2 million in 2021, then retreated by 19.64% to $17.8 million in 2022, then slipped by 4.35% to $17.0 million in 2023.
• Business Quant data shows MRKR's Non-Current Assets at $17.0 million in Q1 2023, $17.8 million in Q4 2022, and $18.7 million in Q3 2022.